46
Participants
Start Date
April 21, 2021
Primary Completion Date
November 30, 2025
Study Completion Date
December 31, 2025
Zimberelimab
Zimberelimab (AB122) is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets PD-1.
Domvanalimab
Domvanalimab (AB 154) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets TIGIT.
Placebo
Saline placebo comparator for pre-surgery treatment in cohort B4
University of California San Francisco, San Francisco
Yale University, New Haven
Dana Farber Cancer Institute, Boston
Collaborators (1)
National Cancer Institute (NCI)
NIH
Arcus Biosciences, Inc.
INDUSTRY
Yale University
OTHER